Milestone Pharmaceuticals Inc. (MIST) stock
MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.46+0.05 (+11.42%)
Close on Nov 18, 2026Market cap $57.32MP/E –Yield –
Milestone Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Milestone Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$78.38M. For fiscal 2025 it was -$62.14M. The highest annual figure on record is -$23.82M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.14M | – |
| FY2024 | Dec 31, 2024 | -$42.10M | – |
| FY2023 | Dec 31, 2023 | -$61.10M | – |
| FY2022 | Dec 31, 2022 | -$59.64M | – |
| FY2021 | Dec 31, 2021 | -$43.07M | – |
| FY2020 | Dec 31, 2020 | -$50.71M | – |
| FY2019 | Dec 31, 2019 | -$57.88M | – |
| FY2018 | Dec 31, 2018 | -$23.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.44M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.81M | -2460.4% |
| Q1 FY2022 | Mar 31, 2022 | -$14.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.27M | – |
| Q2 FY2021 | Jun 30, 2021 | $712.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.09M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.76M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.79M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.68M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.26M | – |
See a number that looks wrong?